LEXINGTON, Mass.--(BUSINESS WIRE)--Translate Bio, a leading messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced the appointment of John R. Schroer, CFA, as Chief Financial Officer. With 28 years of healthcare investment experience, Mr. Schroer brings expertise in financial strategy and analysis and strong industry relationships to Translate Bio.
“John’s financial expertise and deep industry knowledge make him a strong addition to our leadership team, and I’m excited to welcome him to Translate Bio,” said Ronald Renaud, chief executive officer, Translate Bio. “His experience and insights are important to our continued growth as we focus on advancing our two lead programs into the clinic, expanding our pipeline and building upon our leading technology capabilities.”
Prior to joining Translate Bio, Mr. Schroer served as Healthcare Sector Team Head at Allianz Global Investors in San Francisco where he led its healthcare-focused investment strategy, and research and portfolio management efforts. Previously, he conducted in-depth research in the healthcare industry, advising on strategic, operational, capital structure and management incentive changes in various roles at Schroer Capital, L.P., HealthCor Management, L.P., ITROS Capital Management, LLC, INVESCO Funds Group, and Trust Company of the West. Mr. Schroer earned his B.S. and M.B.A. from the University of Wisconsin-Madison.
“I’m inspired by Translate Bio’s mission to bring innovative treatments to patients and honored to join their leadership team,” said Mr. Schroer. “I look forward to working with the rest of the management team to develop mRNA therapeutics that have the potential to transform life threatening illnesses into manageable chronic conditions.”
About Translate Bio
Translate Bio is a leading mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The Company’s MRT platform is designed to develop product candidates that deliver mRNA carrying instructions to produce intracellular, transmembrane and secreted proteins for therapeutic benefit. The Company believes that its MRT platform is applicable to a broad range of diseases caused by insufficient protein production or where production of proteins can modify disease, including diseases that affect the lung, liver, eye, central nervous system, lymphatic system and circulatory system. The Company’s two lead programs are being developed as treatments for cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency. For more information about the Company, please visit www.translate.bio or on Twitter at @TranslateBio.